Kronos stops work on leukemia drug; Aldeyra shares rally on eczema data; Atavistik Bio’s $40Mnews2023-12-19T15:33:19+00:00December 19th, 2023|Endpoints News|
MarketingRx roundup: Vertex, CRISPR get unintended role in SNL skit; Real Chemistry and cancer society debut AI effortnews2023-12-19T15:26:06+00:00December 19th, 2023|Endpoints News|
Metabolic health and primary care startup Knownwell raises $20M Series A roundnews2023-12-19T14:08:55+00:00December 19th, 2023|Endpoints News|
Lassen Therapeutics reels in $85M Series B for PhII testing in thyroid eye diseasenews2023-12-19T13:00:27+00:00December 19th, 2023|Endpoints News|
Exclusive: Kimia Therapeutics secures $55M to supercharge co-founder’s platform, create ‘next-generation Carmot’news2023-12-19T12:30:56+00:00December 19th, 2023|Endpoints News|
Bluebird eyes up to $250M cash via public offering, invoice salenews2023-12-19T12:28:46+00:00December 19th, 2023|Endpoints News|
Compugen secures licensing deal with Gilead for IL-18 protein antibody cancer program, with $60M upfrontnews2023-12-19T12:10:04+00:00December 19th, 2023|Endpoints News|
Ionis divests commercial EU rights for rare disease candidate to Otsuka for $65M upfrontnews2023-12-19T11:36:22+00:00December 19th, 2023|Endpoints News|
At least three digital health startups will go public in 2024, PitchBook saysnews2023-12-19T05:01:09+00:00December 19th, 2023|Endpoints News|
FDA broadens authorization for Akili’s video game for ADHDnews2023-12-18T19:53:46+00:00December 18th, 2023|Endpoints News|
